20 citations
,
May 1992 in “The Journal of Dermatologic Surgery and Oncology”
Dr. Norwood's analysis highlights the need for careful patient selection and strategic hair transplant design to create a natural-looking hair density.
Hair transplantation improves life quality by addressing scars, aging, and genetic flaws, but is limited by the availability of the patient's own hair for donation.
3 citations
,
February 1997 in “Annals of Plastic Surgery”
The document concludes that successful hair restoration surgery should consider facial proportions and balance, and requires surgical skill, artistic judgment, and realistic goals for a natural look.
Topical Metformin shows potential for regenerating hair follicles and minimizing scarring in hair transplant donor areas, similar to Verteporfin but without its side effects. The discussion suggests considering Metformin for post-hair transplant care, though more human trials are needed.
Hair cloning technology is advancing, with clinical trials for improved methods expected by 2028 and 2029, potentially offering a solution for hair loss if donor follicles remain. Organtech's expansion into other biotech areas may secure funding, but the effectiveness of cloning depends on the availability of androgen-resistant donor follicles.
Hair cloning and injection of dermal papilla cells are discussed, with skepticism about their availability by 2023. Users mention Minoxidil, finasteride, and hair transplants as current treatments.
Hair cloning is humorously discussed as always being 5-7 years away, with skepticism about its near-term availability. Gene editing to reactivate dormant follicles is suggested as a more likely solution within the next ten years.
New hair loss treatments like Shiseido/Replicel and Histogen were discussed, with cautious optimism about their availability by 2018. Setipiprant, Replicel, and Bimatoprost were mentioned as potential treatments expected around 2016-2017.